[HTML][HTML] Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression …
Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …
[引用][C] Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression …
TSK Mok, Y Wu, K Nakagawa, S Kim, J Yang… - Annals of …, 2014 - cir.nii.ac.jp
Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr)
Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib …
Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib …
[HTML][HTML] Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After …
TSK Mok, Y Wu, K Nakagawa, S Kim… - Annals of …, 2014 - annalsofoncology.org
Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …